Morepen Laboratories Limited reported a decline in consolidated net profit to ₹9564.65 lakh for the financial year ended March 31, 2026, compared to ₹11801.54 lakh in the previous year. Total income for the year stood at ₹182700.56 lakh, slightly lower than ₹182993.95 lakh in FY25. On a standalone basis, the net profit for the year was ₹6605.75 lakh, down from ₹10157.52 lakh in the corresponding period of the previous year, while total income increased to ₹170269.01 lakh from ₹157025.49 lakh. The Board of Directors, in its meeting held on Tuesday, May 26, 2026, recommended a final dividend of ₹0.20 per equity share of the face value of ₹2 each for the financial year ended March 31, 2026, subject to the approval of shareholders at the ensuing Annual General Meeting. The statutory auditors, M/s. S. P. Babuta & Associates, issued an audit report with an unmodified opinion on the financial results.

Q4 Financial Performance

Morepen Laboratories reported a year-on-year decline in its Q4 consolidated financial metrics. Net profit for the quarter came in at 157M rupees, compared to 203M rupees in the same period of the previous year. Revenue for the quarter rose to 4.84B rupees from 4.7B rupees year-on-year, reflecting modest top-line growth. However, profitability remained under pressure, with Q4 EBITDA declining sharply to 244M rupees from 423M rupees in the corresponding quarter of the previous year. The Q4 EBITDA margin contracted to 5.04% from 9.1% year-on-year, indicating significant pressure on operating profitability during the quarter.

Full-Year Financial Performance

The annual results reflected a similar trend, with consolidated and standalone profitability declining year-on-year despite revenue holding relatively steady on a consolidated basis. The following table summarises the full-year financial performance:

Business Transfer Agreement Update

The Board approved the Second Addendum to the Business Transfer Agreement dated March 18, 2025, entered into with Morepen Medipath Limited, a subsidiary of the company. The addendum revises the "Appointed Date" for the transfer of the Medical Devices Business on a slump sale basis to April 1, 2026. This revision is due to the time involved in obtaining requisite statutory licenses and regulatory approvals. The transaction is a related party transaction conducted on an arm's length basis.

Cost Auditor Appointment

The Board re-appointed M/s. Vijender Sharma & Co. as Cost Auditors for the financial year ended March 31, 2027, pursuant to the recommendation of the Audit Committee. The remuneration payable to the auditors will be placed before the members for ratification at the ensuing Annual General Meeting.

morepen laboratories has transferred 1,62,000 equity shares of its subsidiary, Morepen Medipath Limited (MML), to Mr. Anubhav Suri, the Head of its Medical Devices Business. The decision follows 15 years of significant growth in the medical devices sector under his leadership. The company stated that the transfer is intended to align Mr. Suri's interests with the long-term growth and strategic objectives of MML, ensuring continuity of leadership as the business expands.

As a result of this transaction, Morepen Laboratories' shareholding in MML has decreased from 60% to 51%. Despite the reduction, MML will continue to remain a subsidiary of the company and will be consolidated in its financial statements. The consideration for the transfer was mutually agreed upon between the parties involved.

The shareholding pattern of MML has been revised following the transfer. Mr. Anubhav Suri, who previously held 0.10% equity shares, now holds 9.10% of the total paid-up share capital. The details of the pre and post-transaction shareholding are outlined below.

The disclosure was made in terms of Regulation 30 read with a SEBI master circular. The company's Corporate Office is located in Gurugram, Haryana, and its Registered Office is in Baddi, Himachal Pradesh.